CLINICAL TRIAL: PACTG 1020-A (VERSION 20):PHASE I/II STUDY OF A NOVEL PROTEASE

临床试验：PACTG 1020-A（版本 20）：新型蛋白酶的 I/II 期研究

• 批准号: 7950583
• 负责人: William Thomas Shearer
• 金额: $ 0.4万
• 依托单位: BAYLOR COLLEGE OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-12-01 至 2009-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7950583
• 关键词: Adolescent; Age; Anti-Retroviral Agents; Calendar; Child; Clinical Research; Clinical Trials; Computer Retrieval of Information on Scientific Projects Database; Funding; Grant; Infant; Institution; Multicenter Studies; Peptide Hydrolases; Phase; Research; Research Personnel; Resources; Sample Size; Source; Treatment Protocols; United States National Institutes of Health; experience; novel; open label

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Phase I/II, open-label multicenter study of BMS-232632 as part of combination antiretroviral regimens. The sample size will be a minimum of 72 subjects and will include HIV-infected infants, children, and adolescents ages 3 calendar months and 1 day to 21 years, who are either ART-nanve or ART-experienced.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目和 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 BMS-232632 作为联合抗逆转录病毒治疗方案的一部分进行 I/II 期开放标签多中心研究。样本量至少为 72 名受试者，包括感染 HIV 的婴儿、儿童和 3 个月零 1 天至 21 岁的青少年，他们要么没有接受过 ART，要么有 ART 经验。